We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
FUJIREBIO

Download Mobile App





AACC 2017 Focus on CRISPR and Futuristic Testing Devices

By LabMedica International staff writers
Posted on 01 Aug 2017
Print article
Image: AACC 2017 focuses largely on clustered regularly interspaced short palindromic repeats (CRISPR), Star Trek-like testing devices, and antibiotic resistance (Photo courtesy of iStock).
Image: AACC 2017 focuses largely on clustered regularly interspaced short palindromic repeats (CRISPR), Star Trek-like testing devices, and antibiotic resistance (Photo courtesy of iStock).
At the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services, over 750 exhibitors displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation. But the focus was largely on clustered regularly interspaced short palindromic repeats (CRISPR), Star Trek-like testing devices, and antibiotic resistance.

Kalorama Information, (New York, NY, USA), an independent medical market research firm, estimates the market for CRISPR to be worth USD 28 billion and believes that gene editing is reaching mainstream testing. According to experts, CRISPR will be first used to treat people for blood-related diseases in a way similar to a bone marrow transplant, but to correct a person’s own blood-producing cells instead of implanting donated ones.

The 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from July 30–August 3, also featured a talk by CRISPR co-inventor Jennifer Doudna, PhD, on the future of genome engineering using this revolutionary tool, as well as a plenary on the clinical lab's critical role in combating the antibiotic resistance crisis.

Among the exhibitors at the event was Final Frontier Medical Devices, which presented its real-life Star Trek tricorder for the first time at a U.S. scientific conference. The mobile health device, named DxtER, weighs less than five pounds and allows users to monitor five real-time health vital signs and diagnose 34 diseases without the help of a clinician.

Related Links:
Kalorama Information

Gold Supplier
Coronavirus Array
Extended Coronavirus Array
New
SARS-CoV-2/Influenza A & B/RSV Test
BIOSYNEX® AMPLIQUICK® SARS-COV-2 and Respiratory Triplex
SARS-CoV-2 Antigen Test
ESPLINE SARS-CoV-2 Antigen Test
SARS-CoV-2 Antibody Test
EliA SARS-CoV-2-Sp1 IgG test

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.